DigestRedComo funciona
Red
/
Empresas
Me
No verificado

Merck

Sobre qué escribimos

BiotecnologíaFarmacéuticaIndustriaMedicina - VariosSalud

35 Comunicados de prensa

Ver todos los comunicados de prensa
30/04/2026
Merck Announces First Dose in Phase 3 Study with Enpatoran for Lupus Patients with Active Skin Manifestations
Fuente
Merck
Editor
Business Wire
1.00
0
21/04/2026
Anuncios breves
Merck Launches First Bio-Based Solvent Portfolio for High-Performance Liquid Chromatography
Fuente
Merck
Editor
GLOBENEWSWIRE
1.00
0
01/04/2026
Anuncios breves
Merck Completes Acquisition of JSR Life Sciences’ Chromatography Business, Expanding Protein A Capabilities and Downstream Portfolio
Fuente
Merck
Editor
GLOBENEWSWIRE
1.00
0
18/03/2026
Anuncios breves
Merck Marks 10 Years of SPARK™ Mobilizing Employee Volunteers to Help Inspire the Next Generation in STEM
Fuente
Merck
Editor
GLOBENEWSWIRE
1.00
0
12/01/2026
Eventos
Industria
Salud
Farmacéutica
Medicina - Varios
Oncología
FDA Accepts New Drug Application for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor
Fuente
Merck
Editor
Business Wire
1.00
0
12/01/2026
Eventos
Industria
Salud
Farmacéutica
Medicina - Varios
Oncología
FDA Accepts New Drug Application for Pimicotinib for the Treatment of Tenosynovial Giant Cell Tumor
Fuente
Merck
Editor
Business Wire
1.00
0
22/12/2025
Oncología
Automóvil/Automoción
Salud
Sanidad
Farmacéutica
Industria
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor
Fuente
Merck
Editor
Business Wire
1.00
0
24/11/2025
Industria
Material médico sanitario
Salud
Sanidad
Medicina - Varios
Farmacéutica
Merck Takes Patient-Directed Approach to Bring Innovation to the Treatment of Rare Neuromuscular Disorder, Generalized Myasthenia Gravis
Fuente
Merck
Editor
Business Wire
1.00
0
28/10/2025
Merck Partners with Promega to Advance 3-D Cell Drug Discovery Technologies
Fuente
Merck
Editor
Business Wire
1.00
0
17/10/2025
Oncología
Salud
Sanidad
Medicina - Varios
Farmacéutica
Biotecnología
Industria
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT
Fuente
Merck
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0